

Human CellExp™ LIFR /CD118, human recombinant

CATALOG #:	7444-20	20 µg
	7444-100	100 µg
ALTERNATE NAMES:	LIFR, CD118, FLJ98106, FLJ99923, LIF-R, SJS2, STWS, SWS, Leukemia inhibitory factor receptor, Cluster of Differentiation 118	
SOURCE:	HEK 293 cells (Gln 45 – Ser 833)	
PURITY:	≥ 96% by SDS-PAGE gel	
MOL. WEIGHT:	This protein is fused with the Fc region of human IgG1 at the CT. The reduced monomer has a calculated molecular mass of 115.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhLIFR-Fc monomer is approximately 135-150 kDa due to the glycosylation.	
ENDOTOXIN LEVEL:	<1 EU/µg by LAL method	
FORM:	Lyophilized	

FORMULATION: Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization.


STORAGE CONDITIONS: Store at -20°C. After reconstitution, aliquot and store at -20°C and use within 3 months. Avoid repeated freezing and thawing cycles.

RECONSTITUTION: Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.

DESCRIPTION: Leukemia inhibitory factor receptor also known as LIFR; CD118; FLJ98106; FLJ99923; LIF-R; SJS2; STWS; SWS, is the receptor for leukemia inhibitory factor (LIF). The leukemia inhibitory factor is a polyfunctional cytokine that affects the differentiation, survival, and proliferation of a wide variety of cells in the adult and the

composed of a low-affinity LIF binding chain (LIF receptor) and a high-affinity converter subunit, gp130. Both LIFR and gp130 are members of a family of cytokine receptors that includes components of the receptors for the majority of hematopoietic cytokines and for cytokines that affect other systems, including the ciliary neurotrophic factor, growth hormone and prolactin. Defects in LIFR are the cause of Stueve-Wiedemann syndrome (SWS), a severe autosomal recessive condition and belongs to the group of the bent-bone dysplasias.

BIOLOGICAL ACTIVITY: Measured by its ability to inhibit LIF-dependent proliferation of TF1 human erythroleukemic cells. The ED₅₀ for this effect is typically 5-10 µg/ml in the presence of 0.3 ng/ml of recombinant human LIF.



RELATED PRODUCTS:

- Human CellExp™ CD223, human recombinant (**Cat. No. 7278-10, -50**)
- Human CellExp™ CD71, human recombinant (**Cat. No. 7279-10, -50**)
- Human CellExp™ CD273, human recombinant (**Cat. No. 7369-10, -50**)
- Human CellExp™ CD33, human recombinant (**Cat. No. 7370-10, -50**)
- Human CellExp™ CD36, human recombinant (**Cat. No. 7371-10, -50**)
- Human CellExp™ CD87, human recombinant (**Cat. No. 7372-20, -100**)
- Human CellExp™ CD360, human recombinant (**Cat. No. 7373-20, -100**)
- Human CellExp™ CD244, human recombinant (**Cat. No. 7374-10, -50**)
- Human CellExp™ CD304, human recombinant (**Cat. No. 7375-10**)
- Human CellExp™ CD319, human recombinant (**Cat. No. 7376-10, -50**)
- Human CellExp™ CD306, human recombinant (**Cat. No. 7377-10, -50**)
- Human CellExp™ CD84, human recombinant (**Cat. No. 7378-10, -50**)

FOR RESEARCH USE ONLY! Not to be used in humans.